Skip to content
Companies

Reprise Biomedical

Pig liver collagen scaffolds for deep wounds

Raised to date

$9.2M

of $10M offered across 2 Form D filings

Still open
$754K
Investors
4
Last filed
Jul 1, 2026

About

Reprise Biomedical is an early-commercial-stage biologics company in Plymouth, Minnesota, founded in 2019. It makes biologic wound and surgical matrices from porcine liver using a patented perfusion decellularization process. The process cannulates the liver's native vasculature and perfuses a mild detergent solution through the vessels, stripping cells while leaving an intact collagen scaffold with preserved vasculature. The resulting Miro product family is sold for deep, tunneling and undermining wounds and for soft tissue repair.

Perfusion decellularization through the organ's own blood vessels rather than immersion in chemicals, which lets the company produce thick (up to 2 cm) collagen scaffolds with retained vasculature and strength instead of the thin sheets immersion methods are limited to.

Funding

  • EquityFiled Jul 1, 2026Form D/A
    $9.2M/ $10M
  • EquityFiled May 21, 2026Form D
    $1.4M/ $8M

Product

Miro3D Wound Matrix

Biologic wound matrix / medical device

A 2 cm thick porcine-liver-derived collagen scaffold with preserved vasculature, designed to fill deep, tunneling and undermining wounds that thin sheet grafts cannot address.

  • 2 cm thick collagen scaffold
  • Retained native vasculature within the scaffold
  • Supports cellular integration and ingrowth

Built for

Wound care clinics, hospitals and surgeons treating chronic and complex wounds

People on file